Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone for HBV-related acute liver failure and early acute-on-chronic liver failure
ChiCTR2600124066Phase 4Recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexamethasone in fulminant hepatitis, acute-on-chronic liver failure (ACLF) and hepatitis B (HBV) (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: 28-day mortality rate for patients without liver transplantation. Started May 2026; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
fulminant hepatitisacute-on-chronic liver failure (ACLF)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2600124066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124066.